Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice
Files
(Published Version)
Date
2018
Authors
Xie, V.
Tong, D.
Wallington-Beddoe, C.T.
Bradstock, K.F.
Bendall, L.J.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Biomarker Research, 2018; 6(6):1-7
Statement of Responsibility
Vicki Xie, Daochen Tong, Craig T. Wallington-Beddoe, Ken F. Bradstock and Linda J. Bendall
Conference Name
Abstract
Sphingosine kinase (SphK) 2 has been implicated in the development of a range of cancers and inhibitors of this enzyme are currently in clinical trial. We have previously demonstrated a role for SphK2 in the development of acute lymphoblastic leukemia (ALL).In this and our previous study we use mouse models: in the previous study the disease was driven by the proto-oncogene BCR/ABL1, while in this study cancer risk was elevated by deletion of the tumor suppressor ARF.Mice lacking ARF and SphK2 had a significantly reduced incidence of ALL compared mice with wild type SphK2.These results show that the role of SphK2 in ALL development is not limited to BCR/ABL1 driven disease extending the potential use of inhibitors of this enzyme to ALL patients whose disease have driver mutations other than BCR/ABL1.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.